CN
111.png
banner
Your present location:Home/About us/News/Company/CfDNA methylation sequencing is of great value for early screening of cancer

CfDNA methylation sequencing is of great value for early screening of cancer

Release date:2023-06-12

Unintrusive multi-cancer detection by circulating cell-free DNA methylation

sequencing (THUNDER): development and independent validation studies

Published:February 25, 2023

DOI:https://doi.org/10.1016/j.annonc.2023.02.010

Highlights

• MCDBT-1 had a sensitivity of 69.1% and a specificity of 98.9% in detecting six cancers.

• In the real world, MCDBT-1 decreased late-stage incidence by 38.7%-46.4% and increased 5-year survival rate by 33.1%-40.4%.

• In parallel, MCDBT-2 was set at a lower specificity but a higher sensitivity than MCDBT-1 and had an ideal performance.

Background

Early detection of cancer offers the opportunity to identify candidates when curative treatments are achievable. The THUNDER study (THe UNintrusive Detection of EaRly-stage cancers, NCT04820868) aimed to evaluate the performance of enhanced linear-splinter amplification sequencing, a previously described cell-free DNA (cfDNA) methylation-based technology, in the early detection and localization of six types of cancers in the colorectum, esophagus, liver, lung, ovary, and pancreas.

Patients and methods

A customized panel of 161 984 CpG sites was constructed and validated by public and in-house (cancer: n = 249; non-cancer: n = 288) methylome data, respectively. The cfDNA samples from 1693 participants (cancer: n = 735; non-cancer: n = 958) were retrospectively collected to train and validate two multi-cancer detection blood test (MCDBT-1/2) models for different clinical scenarios. The models were validated on a prospective and independent cohort of age-matched 1010 participants (cancer: n = 505; non-cancer: n = 505). Simulation using the cancer incidence in China was applied to infer stage shift and survival benefits to demonstrate the potential utility of the models in the real world.

Results

MCDBT-1 yielded a sensitivity of 69.1% (64.8%-73.3%), a specificity of 98.9% (97.6%-99.7%), and tissue origin accuracy of 83.2% (78.7%-87.1%) in the independent validation set. For early-stage (I-III) patients, the sensitivity of MCDBT-1 was 59.8% (54.4%-65.0%). In the real-world simulation, MCDBT-1 achieved a sensitivity of 70.6% in detecting the six cancers, thus decreasing late-stage incidence by 38.7%-46.4%, and increasing 5-year survival rate by 33.1%-40.4%, respectively. In parallel, MCDBT-2 was generated at a slightly low specificity of 95.1% (92.8%-96.9%) but a higher sensitivity of 75.1% (71.9%-79.8%) than MCDBT-1 for populations at relatively high risk of cancers, and also had ideal performance.

Conclusion

In this large-scale clinical validation study, MCDBT-1/2 models showed high sensitivity, specificity, and accuracy of predicted origin in detecting six types of cancers.


For details, please visit:https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext


Magen has devleoped a complete solution for Cell free DNA extraction, including DNA/RNA extraction kits, raw materials and automated extraction machines.

Please visit http://www.magen-tec.com/products/list.aspx?lcid=35

Back to list
Leave A Message

Leave A Message

    Please provide us with the information below, and we'll contact you as soon as possible.

This site uses cookies to improve your online experience,allow you to share content on social media,measure traffic to this website and display customised ads based on your browsing activity.